Adoptive regulatory T-cell (Treg) therapy using autologous Tregs expanded ex vivo is a promising therapeutic approach which is currently being investigated clinically as a means of treating various autoimmune diseases and transplant rejection. Despite this, early results have highlighted the need for potent Tregs to yield a substantial clinical advantage. One way to achieve this is to create antigen-specific Tregs which have been shown in pre-clinical animal models to have an increased potency at suppressing undesired immune responses, compared to polyclonal Tregs. This mini review outlines where Treg therapy currently stands and discusses the approaches which may be taken to generate antigen-specific Tregs, including the potential use of chimeric antigen receptors (CARs), for future clinical trials.
Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?
- Views Icon Views
- Share Icon Share
Dominic Boardman, John Maher, Robert Lechler, Lesley Smyth, Giovanna Lombardi; Antigen-specificity using chimeric antigen receptors: the future of regulatory T-cell therapy?. Biochem Soc Trans 15 April 2016; 44 (2): 342–348. doi: https://doi.org/10.1042/BST20150247
Download citation file: